Moderate

Nausea & vomiting in adults — antiemetic choice by cause (mechanism-based antiemetics)

Symptom control · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Rational antiemetic prescribing matches the drug to the dominant emetic pathway/receptor driving the nausea. Key pathways: chemoreceptor trigger zone (D2, 5-HT3 — drugs, toxins, metabolic/biochemical e.g. hypercalcaemia, uraemia, opioids); gut/vagal (5-HT3, D2 — gastric stasis, obstruction, chemo/radiotherapy); vestibular (H1, muscarinic — motion, vertigo); cortical (anxiety, pain, raised ICP); and gastric stasis (prokinetic required). Identify and treat the cause, choose the matched antiemetic, use the parenteral/SC route if vomiting, and review before combining or escalating.

Red flags

  • Vomiting with severe abdominal pain/distension, no flatus/stool — bowel obstruction/perforation
  • Headache, papilloedema, focal neurology, early-morning vomiting — raised ICP
  • Haematemesis / coffee-ground vomiting — GI bleed
  • Features of DKA, hypercalcaemia, uraemia, pregnancy (exclude), or sepsis
  • Signs of significant dehydration / shock / AKI from protracted vomiting

Assessment

Differential diagnosis

  • Drugs/toxins/metabolic (opioids, chemo, antibiotics; hypercalcaemia, uraemia, DKA, hyponatraemia, hepatic/renal failure) — CTZ (D2/5-HT3)
  • Gastric stasis / gastroparesis / functional dyspepsia / partial obstruction — prokinetic (D2)
  • Bowel obstruction (complete/mechanical) — avoid prokinetic if colic; antisecretory
  • Raised intracranial pressure (tumour, bleed) — cyclizine +/- dexamethasone
  • Vestibular (labyrinthitis, BPPV, motion, Meniere) — H1/antimuscarinic
  • Chemotherapy/radiotherapy-induced (5-HT3, NK1, steroid)
  • Anxiety/anticipatory (cortical) — benzodiazepine
  • Pregnancy (manage per hyperemesis pathway), gastroenteritis, post-operative (PONV)

Investigations

  • Identify cause: history (timing, relation to meals/opioids/movement), drug chart, bowel habit
  • Examination: abdomen (distension, succussion splash, obstruction), neuro (papilloedema, focal signs), hydration status
  • Bloods: U&E, calcium, glucose, LFTs, (amylase/lipase, bHCG, drug levels e.g. digoxin as indicated)
  • Erect abdominal/chest X-ray or CT if obstruction/perforation suspected
  • Assess for dehydration and electrolyte disturbance from vomiting (hypokalaemia, metabolic alkalosis)

Management

  • Correct reversible causes: stop/rotate culprit drug, correct hypercalcaemia/hyponatraemia/DKA, relieve obstruction, treat infection, treat constipation
  • Rehydrate and replace electrolytes (IV fluids + potassium as needed)
  • Choose antiemetic by mechanism (see drugs); if vomiting, give IV or SC — oral absorption is unreliable
  • Chemical/metabolic/opioid-induced: haloperidol first-line (or metoclopramide/ondansetron)
  • Gastric stasis/prokinetic needed: metoclopramide or domperidone (avoid if complete obstruction/colic/perforation)
  • Raised ICP / bowel obstruction (no prokinetic): cyclizine; add dexamethasone for ICP or obstruction
  • Vestibular: cyclizine or an antihistamine/antimuscarinic (prochlorperazine, hyoscine)
  • Chemo-induced: 5-HT3 antagonist (ondansetron) + dexamethasone +/- NK1 antagonist (aprepitant)
  • Unknown/multiple causes or refractory: broad-spectrum levomepromazine
  • Combine drugs with complementary (not duplicate) receptor actions; review at 24-48 h before escalating

Drugs & doses

Metoclopramide 10 mg PO/IV/IM/SC up to three times daily (max 5 days; prokinetic/D2; AVOID in complete obstruction, Parkinson's, young women — extrapyramidal/dystonia risk) [verify local dose]
Domperidone 10 mg PO up to three times daily (prokinetic, less CNS penetration; caution QT/cardiac) [verify local dose]
Haloperidol 0.5-1.5 mg PO/SC once or twice daily (or 1.5-5 mg/24 h CSCI) for chemical/metabolic/opioid nausea (D2; watch QT, EPS) [verify local dose]
Cyclizine 50 mg PO/IM/IV/SC up to three times daily (or 100-150 mg/24 h CSCI) for vestibular, raised ICP, bowel obstruction (H1/antimuscarinic; caution heart failure) [verify local dose]
Ondansetron 4-8 mg PO/IV up to twice or three times daily (5-HT3; chemo/radiotherapy, post-op; causes constipation, QT prolongation) [verify local dose]
Prochlorperazine 5-10 mg PO three times daily, or 12.5 mg IM, or 3-6 mg buccal twice daily (vestibular/general; EPS risk) [verify local dose]
Levomepromazine 2.5-6.25 mg PO/SC once or twice daily (or 5-12.5 mg/24 h CSCI) broad-spectrum/refractory (sedation, hypotension) [verify local dose]
Dexamethasone 4-8 mg PO/IV/SC once daily adjunct (raised ICP, bowel obstruction, chemo) [verify local dose]
Hyoscine butylbromide 20 mg SC/IV up to 60-120 mg/24 h for colic/secretions in bowel obstruction [verify local dose]
Aprepitant 125 mg PO day 1 then 80 mg daily (NK1, highly emetogenic chemo) [verify local dose]

Disposition

Depends on cause/severity: discharge with oral antiemetic and safety-net if mild and cause benign; admit for IV fluids/parenteral antiemetics if dehydrated, obstructed, or serious underlying cause.

Complications & pitfalls

  • Dehydration, AKI, hypokalaemia and metabolic alkalosis
  • Aspiration pneumonia, Mallory-Weiss tear, oesophageal rupture
  • Drug side effects: extrapyramidal/dystonia (metoclopramide, prochlorperazine), QT prolongation (ondansetron, haloperidol, domperidone), constipation (ondansetron)
  • Malnutrition if prolonged

Exam pearls

  • Match the drug to the receptor/cause: haloperidol for chemical/metabolic, metoclopramide for stasis, cyclizine for vestibular/ICP/obstruction, ondansetron for chemo/post-op, levomepromazine when unknown/refractory.
  • If the patient is vomiting, give antiemetics parenterally (IV or SC) — not orally.
  • Avoid prokinetics (metoclopramide/domperidone) in complete mechanical bowel obstruction or with colic.
  • Do not combine two drugs with the same receptor action (e.g. cyclizine + hyoscine both antimuscarinic; cyclizine antagonises metoclopramide's prokinetic effect).
  • Guidance: Palliative Care Formulary, Scottish Palliative Care Guidelines, NICE CKS N&V. Evidence that cause-based selection beats empirical is weak but it is standard, rational practice.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.